Immix Biopharma, Inc. (IMMX) Stock Score, Valuation & Financial Research

Immix Biopharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for IMMX

Immix Biopharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 9.64. These figures are a research snapshot, not a buy or sell recommendation.

What Immix Biopharma, Inc. does

Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Immix Biopharma is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model is focused on the research, discovery, and development of novel cell therapies, specifically chimeric antigen receptor cell therapy (CAR-T) platforms, to treat serious diseases such as light chain (AL) amyloidosis and other hematologic malignancies.

Products and services

  • The company's primary product candidate is NXC-201, a next-generation, sterically optimized CAR-T cell therapy designed to treat relapsed/refractory light chain (AL) amyloidosis.

Brands and product families

  • NXC-201 — Lead clinical-stage CAR-T cell therapy candidate. Source
  • N-GENIUS — Proprietary platform for the development of CAR-T therapies. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical-stage product candidates. Source

Business strengths to evaluate

  • N-GENIUS platform technology Source
  • FDA Regenerative Medicine Advanced Therapy (RMAT) designation for NXC-201 Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on the success of a single lead product candidate, NXC-201 Source
  • Need for additional capital to fund research and development Source

Sources: Company research source · FDA Regenerative Medicine Advanced Therapy (RMAT) designation for NXC-201

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

IMMX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 9.64
Market capitalization:
524.43M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -39.92M
Free cash flow:
USD -24.66M
Cash:
USD 225.49M
Total debt:
USD 1M
EPS:
USD -0.88

What stands out

  • Free cash flow is USD -24.66M, negative for the stored period.
  • The balance sheet shows USD 225.49M of cash versus USD 1M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 224.49M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IMMX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can IMMX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IMMX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IMMX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of IMMX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research IMMX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.